Literature DB >> 1515415

Analysis of the DNA binding and transcriptional activation properties of the Ets1 oncoprotein.

A Gegonne1, B Punyammalee, B Rabault, R Bosselut, S Seneca, M Crabeel, J Ghysdael.   

Abstract

The c-ets1 gene product (Ets1) is the prototype of a family of sequence-specific transcriptional activators which have been implicated in various developmental processes and in the response of cells to a variety of extracellular stimuli. We report here a structure-function analysis of the DNA binding and transcriptional activation properties of Ets1. The minimal region required for specific DNA binding is located at the carboxy-terminus of Ets1, a domain highly conserved in all known members of the Ets family. Transcriptional activation by Ets1 in mammalian cells requires an additional domain of 110 amino acids characterized by a high content of acidic residues and localized in the amino-terminal half of the protein. This domain also functions as a transcriptional activation domain in yeast cells when linked to the heterologous DNA binding domain of Gal4. In contrast to its conservation in Ets1 proteins across vertebrate species, this activation domain is not conserved in other members of the Ets family. These results indicate that an important level of specificity between different members of the Ets family may reside in the differential interactions of their respective activation domains with distinct general transcription factors or different associated coactivators.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1515415

Source DB:  PubMed          Journal:  New Biol        ISSN: 1043-4674


  17 in total

1.  Correlated motions and interactions at the onset of the DNA-induced partial unfolding of Ets-1.

Authors:  Hiqmet Kamberaj; Arjan van der Vaart
Journal:  Biophys J       Date:  2009-02-18       Impact factor: 4.033

2.  Context dependent transactivation domains activate the immunoglobulin mu heavy chain gene enhancer.

Authors:  B Erman; R Sen
Journal:  EMBO J       Date:  1996-09-02       Impact factor: 11.598

3.  Regulation of expression of the human beta-1,2-N-acetylglucosaminyltransferase II gene (MGAT2) by Ets transcription factors.

Authors:  W Zhang; L Revers; M Pierce; H Schachter
Journal:  Biochem J       Date:  2000-04-15       Impact factor: 3.857

4.  A single amino-acid substitution in the Ets domain alters core DNA binding specificity of Ets1 to that of the related transcription factors Elf1 and E74.

Authors:  R Bosselut; J Levin; E Adjadj; J Ghysdael
Journal:  Nucleic Acids Res       Date:  1993-11-11       Impact factor: 16.971

5.  Transcriptional activation of the human T-lymphotropic virus type I long terminal repeat by functional interaction of Tax1 and Ets1.

Authors:  S D Gitlin; J Dittmer; R C Shin; J N Brady
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

6.  Real-time DNA binding measurements of the ETS1 recombinant oncoproteins reveal significant kinetic differences between the p42 and p51 isoforms.

Authors:  R J Fisher; M Fivash; J Casas-Finet; J W Erickson; A Kondoh; S V Bladen; C Fisher; D K Watson; T Papas
Journal:  Protein Sci       Date:  1994-02       Impact factor: 6.725

7.  DNA-binding and transcriptional activation properties of the EWS-FLI-1 fusion protein resulting from the t(11;22) translocation in Ewing sarcoma.

Authors:  R A Bailly; R Bosselut; J Zucman; F Cormier; O Delattre; M Roussel; G Thomas; J Ghysdael
Journal:  Mol Cell Biol       Date:  1994-05       Impact factor: 4.272

Review 8.  Review of Ets1 structure, function, and roles in immunity.

Authors:  Lee Ann Garrett-Sinha
Journal:  Cell Mol Life Sci       Date:  2013-01-05       Impact factor: 9.261

9.  A residue of the ETS domain mutated in the v-ets oncogene is essential for the DNA-binding and transactivating properties of the ETS-1 and ETS-2 proteins.

Authors:  N Soudant; O Albagli; P Dhordain; A Flourens; D Stéhelin; D Leprince
Journal:  Nucleic Acids Res       Date:  1994-09-25       Impact factor: 16.971

10.  Ets-1 is required for the activation of VEGFR3 during latent Kaposi's sarcoma-associated herpesvirus infection of endothelial cells.

Authors:  Kimberley D Gutierrez; Valerie A Morris; David Wu; Serge Barcy; Michael Lagunoff
Journal:  J Virol       Date:  2013-04-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.